NEW YORK, Feb 18 (Reuters) – ARYx Therapeutics Inc
, a U.S. biopharmaceutical company, said on Thursday it
is exploring strategic options after advanced talks over the
licensing of its oral antiarrythmic agent, budiodarone, fell
through.
Performance Optimization WordPress Plugins by W3 EDGE
